Cite

HARVARD Citation

    He, C. et al. (2022). A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus. MedComm. 2 (3), pp. 430-441. [Online]. 
  
Back to record